Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 7:10:185.
doi: 10.1186/1471-2407-10-185.

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer

Karina Dahl Steffensen  1 , Marianne Waldstrøm, Rikke Kølby Christensen, Annette Bartels, Nils Brünner, Anders Jakobsen
Affiliations

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer

Karina Dahl Steffensen et al. BMC Cancer. .

Abstract

Background: Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a natural inhibitor of the matrix metalloproteinases (MMPs) which are proteolytic enzymes involved in degradation of extracellular matrix thereby favoring tumour cell invasion and metastasis. TIMP-1 activity in tumour tissue may therefore play an essential role in the progression of a malignant tumour.The primary aim of the present study was to evaluate TIMP-1 protein immunoreactivity in tissue from primary ovarian cancer patients and associate these findings with the course of the disease including response to treatment in the individual patient.

Methods: TIMP-1 was assessed by immunohistochemistry (in tissue micro arrays) in a total of 163 ovarian cancer specimens obtained from primary debulking surgery during 1991-1994 as part of a randomized clinical protocol.

Results: Positive TIMP-1 immunoreactivity was found in 12.3% of the tumours. The median survival time for the 143 patients with TIMP-1 negative tumours was 23.7 months [19.0-29.4] 95% CI, while the median survival time for the 20 patients with TIMP-1 positive tumours was 15.9 months [12.3-27.4] 95% CI. Although a difference of 7.8 months in median overall survival in favor of the TIMP-1 tumour negative patients was found, this difference did not reach statistical significance (p = 0.28, Kaplan-Meier, log-rank test). Moreover, TIMP-1 immunoreactivity was not associated with CA125 response (p = 0.53) or response at second look surgery (p = 0.72).

Conclusion: TIMP-1 immunoreactivity in tumour tissue from patients with primary epithelial ovarian cancer did not correlate with patient survival or response to combination platinum/cyclophosphamide therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TMA used for TIMP-1 immunohistochemistry
Figure 2
Figure 2
TIMP-1 immunohistochemical staining. A. Negative TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=0 (absent) and percentage positive cells =0 (no tumor cells with staining). B. Negative TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=1 (weak) and percentage positive cells =2 (between >10% and 25% tumor cells with staining). C. Negative TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=2 (moderate) and percentage positive cells =1 (between >0% and 10% tumor cells with staining). D. Positive TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=2 (moderate) and percentage positive cells =4 (>50% tumor cells with staining). E. Positive TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=3 (strong) and percentage positive cells =3 (between >25% and 50% tumor cells with staining).
Figure 3
Figure 3
Kaplan Meier Overall Survival (OS) curves and TIMP-1. Median OS for patients with TIMP-1 negative tumours (N = 139): 23.7 months [19.0-29.4] 95% CI. Median OS for patients with TIMP-1 positive tumours (N = 21): 15.9 months [12.3-27.4] 95% CI.
See this image and copyright information in PMC

References

    1. Moller SN, Vejgaard SI, Ornbjerg WS, Schrohl AS, Dowell B, Davis G, Jarle CI, Nielsen HJ, Brunner N. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol. 2008;10:774–786. doi: 10.1080/00365520701878163. - DOI - PubMed
    1. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol. 1991;10:679–685. doi: 10.1111/1523-1747.ep12483956. - DOI - PubMed
    1. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;10:6267–6275. - PubMed
    1. Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003;10:40364–40372. doi: 10.1074/jbc.M302999200. - DOI - PubMed
    1. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998;10:2002–2010. doi: 10.1172/JCI2881. - DOI - PMC - PubMed

Publication types

MeSH terms